Skip to main content

Jiaoti Huang

Johnston-West Distinguished Professor of Pathology
Pathology

Overview


I am a physician-scientist with clinical expertise in the pathologic diagnosis of genitourinary tumors including tumors of the prostate, bladder, kidney and testis. Another area of interest is gynecologic tumors. In my research laboratory we study prostate cancer, focusing on molecular mechanisms of carcinogenesis and tumor progression, as well as biomarkers, imaging and novel therapeutic strategies. In addition to patient care and research, I am also passionate about education. I have trained numerous residents, fellows, graduate students and postdocs.

Current Appointments & Affiliations


Johnston-West Distinguished Professor of Pathology · 2018 - Present Pathology, Clinical Science Departments
Chair · 2016 - Present Pathology, Clinical Science Departments
Professor of Pathology · 2016 - Present Pathology, Clinical Science Departments
Professor of Pharmacology and Cancer Biology · 2017 - Present Pharmacology & Cancer Biology, Basic Science Departments
Professor of Cell Biology · 2022 - Present Cell Biology, Basic Science Departments
Member of the Duke Cancer Institute · 2016 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published March 7, 2023
A New Avenue for Prostate Cancer Treatment
Published January 18, 2022
Early Prostate Cancers Can Harbor Aggressive Tumor Cells
Published March 23, 2021
Duke Research Points to New Therapy Approach to Cut Off Prostate Cancer's Fuel Source

View All News

Recent Publications


Revisiting the use of CK7 and CK20 immunohistochemical stains in pathological diagnoses.

Journal Article Diagn Pathol · April 11, 2025 BACKGROUND: Cytokeratin-7 (keratin-7; CK7) and cytokeratin-20 (keratin-20; CK20) have been among the most widely used markers in pathology for prediction of tumor site of origin or classification. However, with the increased availability of newer and more ... Full text Link to item Cite

Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone.

Journal Article Clin Cancer Res · April 1, 2025 PURPOSE: After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, ... Full text Link to item Cite

Supplementary Table S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone

Other · April 1, 2025 <p>Primary antibodies used for immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB)</p> ... Full text Cite
View All Publications

Recent Grants


Targeting Undruggable Transcription Factor HoxB13 to Inhibit Prostate Cancer Metastasis

ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2029

Testing ATAD2 as a new therapeutic target for advanced prostate cancer

ResearchPrincipal Investigator · Awarded by University of California - Los Angeles · 2024 - 2029

Elucidating alternative polyadenylation regulation during prostate cancer progression to castration-resistance

ResearchCo Investigator · Awarded by National Institutes of Health · 2024 - 2029

View All Grants

Education, Training & Certifications


New York University · 1991 Ph.D.
Anhui Medical University (China) · 1983 M.D.

External Links


Huang Laboratory